Tag Archives: CARA

Hot Biotech Stocks For 2019

Drugs that help the immune system fight cancer are making a big difference for scores of patients, and stocks tied to companies developing them have done wonders for quite a few portfolios. The Loncar Cancer Immunotherapy Index, which tracks a revolving basket of drugmaker stocks that fit in this niche, is up 31.5% over the past year.

The general outlook for immuno-oncology is so bright that the niche index has thumped the broad market and the Nasdaq Biotechnology Index over the past year.

^LCI data by YCharts.

The strong patient responses we’ve seen from revolutionary new drugs combined with a frothy market for biotech buyouts have sent quite a few stocks skyward. Before you jump into the fray, though, you should understand a couple of challenges that many immuno-oncology stocks will face on the road ahead. 

A tough act to follow

From a commercial standpoint, the most successful class of drugs that help the immune system fight cancer are the PD-1 inhibitors. Opdivo, from Bristol-Myers Squibb (NYSE:BMY), and Keytruda, from Merck & Co. (NYSE:MRK), weren’t available a few years ago. But the pair will probably generate a combined $12 billion in sales this year.

Hot Biotech Stocks For 2019: Fonar Corporation(FONR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Fonar Co. (NASDAQ:FONR) Treasurer Raymond V. Damadian sold 1,320 shares of the firm’s stock in a transaction on Monday, June 25th. The shares were sold at an average price of $27.47, for a total value of $36,260.40. Following the completion of the transaction, the treasurer now owns 127,802 shares in the company, valued at approximately $3,510,720.94. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

  • [By Logan Wallace]

    Fonar Co. (NASDAQ:FONR) Treasurer Raymond V. Damadian sold 2,400 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $24.50, for a total value of $58,800.00. Following the sale, the treasurer now directly owns 123,202 shares in the company, valued at approximately $3,018,449. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

  • [By Shane Hupp]

    Fonar Co. (NASDAQ:FONR) Treasurer Raymond V. Damadian sold 900 shares of the stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $24.68, for a total value of $22,212.00. Following the completion of the sale, the treasurer now directly owns 121,852 shares of the company’s stock, valued at $3,007,307.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Hot Biotech Stocks For 2019: Genuine Parts Company(GPC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Gunpowder Capital Corp (CNSX:GPC) hit a new 52-week low on Wednesday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 3000 shares. The stock had previously closed at C$9.90.

  • [By ]

    Genuine Parts Company (NYSE: GPC), a distributor of automotive replacement parts in the United States and abroad, most recently raised its dividend payout by about 7 percent and it now yields 2.9 percent. GPC has paid a cash dividend every year since going public in 1948, and 2018 marks the 62nd consecutive year of dividend hikes.

  • [By Joseph Griffin]

    Shares of Genuine Parts (NYSE:GPC) have earned an average rating of “Hold” from the ten ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $99.40.

Hot Biotech Stocks For 2019: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of Cara Therapeutics (NASDAQ:CARA) rose over 17% last month, according to data provided by S&P Global Market Intelligence. The company announced that it had completed enrollment for its phase 3 clinical trial evaluating its lead drug candidate, Korsuva, as a potential treatment for chronic kidney disease-associated pruritus (CKD-aP) in patients on dialysis. That means top-line results from the study will be available sometime in the second quarter of 2019. 

  • [By Max Byerly]

    Cara Therapeutics Inc (NASDAQ:CARA) has earned an average recommendation of “Buy” from the seventeen analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $24.96.

  • [By Cory Renauer]

    Marijuana and opioids have been used to treat serious ailments for an awfully long time, and they’re about to get some important upgrades. Some investors are convinced GW Pharmaceuticals PLC (NASDAQ:GWPH) and Cara Therapeutics Inc. (NASDAQ:CARA) have found the right way to improve on some old favorites.

  • [By Brian Orelli]

    Shares of Cara Therapeutics (NASDAQ:CARA) jumped 26.3% in May, according to data provided by S&P Global Market Intelligence, after the biotech signed a partnership with Vifor Fresenius Medical Care Renal Pharma to license most of the ex-U.S. rights to Korsuva, Cara’s treatment for itching associated with chronic kidney disease in dialysis patients.

  • [By Ethan Ryder]

    Cara Therapeutics Inc (NASDAQ:CARA) SVP Frederique Ph.D. Menzaghi sold 3,000 shares of the stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $19.81, for a total transaction of $59,430.00. Following the transaction, the senior vice president now directly owns 98,000 shares in the company, valued at approximately $1,941,380. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

  • [By Keith Speights]

    One such biotech is GW Pharmaceuticals (NASDAQ:GWPH), which already has one cannabinoid product on the market in some countries and another one potentially on the way to approval in the U.S. Another biotech, Cara Therapeutics (NASDAQ:CARA), has a pre-clinical candidate cannabinoid-receptor agonist, CR701, which puts it ever-so-loosely in the marijuana stock category.

Top 10 Stocks To Watch For 2018

Macy’s (M) stock was slammed after its Investor Meeting, as reports focused on its gross margin challenges. However, it appears that Macy’s comparable store sale performance has improved compared to previous months and it looks quite capable of reaching its sales guidance for the full year. I believe that the market is now viewing Macy’s too negatively, putting too much weight on a weak February (which was likely influenced by delayed tax refunds) that made its Q1 comps quite weak and also temporarily affected its gross margins.

Comparable Store Sales Trends

Macy’s indicated that its May YTD (February to May) comparable store sales (owned plus licensed) improved by around 1% from its Q1 comparable store sales. As May has historically represented around 24% to 25% of Macy’s sales in the first four months, this means that May’s comps need to be approximately 4% better than Q1 comps to improve May YTD comps by 1%.

Thus, May’s comps (owned plus licensed) are estimated to be -0.6%. Based on Macy’s comments about how March/April performed a bit over 1% better than Q1’s average, we can also estimate that Macy’s owned plus licensed comps were around -7.4% in February and -3.4% in March/April. This leads to an estimate of -2.5% comps for the March to May period.

Top 10 Stocks To Watch For 2018: S&P Smallcap 600(PH)

Advisors’ Opinion:

  • [By Charles Mizrahi, President and CEO, Hampton Investors, Inc.]

    Parker Hannifin (PH) generates strong revenue from its aerospace division, while its primary industrial segment is lagging.

    Overall, we like the company’s balanced portfolio. PH had solid order rates this past year with backlog of $3.6 billion between its industrial and aerospace segments.

Top 10 Stocks To Watch For 2018: Carnival Corporation(CUK)

Advisors’ Opinion:

  • [By Rick Munarriz]

    Carnival Corporation & plc (NYSE:CCL) (NYSE:CUK)shareholders have to be feeling pretty good these days. The stock hit yet another new high on Friday, and the stock is trading 13% higher so far in 2017.It’s been smooth sailing so far this year, but the first big test comes on Tuesday morning when the world’s largest cruise line operator reports financial results for its fiscal first quarter.

Top 10 Stocks To Watch For 2018: Universal Health Services, Inc.(UHS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Universal Health Services (UHS) tumbled to the bottom of the S&P 500 today after BuzzFeed published an investigative story alleging that the company’s psychiatric hospitals put profits ahead of people.

    Getty Images

    Shares of Universal Health Services dropped 12% to$111.30 today, while the S&P 500 rose 1.3% to 2,241.35, a record high.

    Universal Health Services’ stock had been minding its business for most of the day–it was up 1.1% at $127.76 at 3:10 p.m. today–when the story by BuzzFeed’s Rosalind Adams went live. Here’s the gist:

    Millwood Hospital is part of Americas largest psychiatric hospital chain, Universal Health Services, or UHS. Its more than 200 psychiatric facilities across the country admitted nearly 450,000 patients last year. The result was almost $7.5 billion in revenues from inpatient care last year and profit margins of around 30%. More than a third of the companys overall revenue from both medical hospitals and psychiatric facilities comes from taxpayers through Medicare and Medicaid.

    A yearlong BuzzFeed News investigation based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents raises grave questions about the extent to which those profits were achieved at the expense of patients.

    Universal Health Services market capitalization dropped to $10.7 billion today from $12.3 billion yesterday. It reported net income of $680 million on sales of $9 billion in 2015.

  • [By Ben Levisohn]

    Universal Health Services (UHS) slumped to the bottom of the S&P 500 today after getting downgraded by Raymond James.

    Pixabay

    Universal Health Servicesdropped 6.8% to $101.55 today, while the S&P 500 fell 0.8% to 2,253.28.

    Raymond James analyst John Ransom and team explain why they cut Universal Health Services to Market Perform from Outperform:

    We are lowering our rating onUniversal Health Services to a Market Perform (from an Outperform) due to an escalation in events surrounding last weeks Buzzfeed article. Last Friday (12/9), Senator Grassley, Chair of the Judiciary Committee, sent a letter…to the office of inspector general regarding details of the current federal investigation into Universal Health Services. Specifically, the letter rehashes the Buzzfeed article and requests an update on the investigation by Dec. 23. Our view is that – even ifUniversal Health Services management is correct on the legalities – we think the entrance of the venerable Senator Grassley into the mix takes the political risk to a more dangerous level. Plus – even if “suicide ideation” doesn’t generate additional revenues per admission, we think it’s possible that the heightened political scrutiny could invite more caution and/or red tape into the admissions process – either externally or from self-policing. Add in the ongoing OIG investigation, and we think the risk-reward is no longer compelling.

    Universal Health Services’ market capitalization fell to $9.8 billion today from $10.6 billion yesterday. It reported net income of $680 million on sales of $9 billion in 2015.

  • [By Ben Levisohn]

    Universal Health Services (UHS), yesterday’s biggest loser, soared to the top of the S&P 500 today as it rebounded from the massive selloff.

    Agence France-Presse/Getty Images

    Universal Health Servicesgained 6.9% to $108.57 today, while the S&P 500 rose 0.4% to 2,262.03.

    Weakness in Universal Health Services began when Buzzfeed ran an article last week, contending the companys psychiatric hospitals put profits ahead of people. Yesterday, it tumbled when Raymond James cut its rating on the stock due to problems that could be caused by a potential Senate investigation.

    Universal Health Services’ market capitalization rose to $10.5 today from $9.8 billion yesterday, nearly recouping its drop from $10.6 billion on Dec. 13.

    It reported net income of $680 million on sales of $9 billion in 2015.

  • [By Benzinga News Desk]

    Goldman Sachs (NYSE: GS) has at least one billion reasons to hope President Trump’s paring back of Dodd-Frank will include the Volcker Rule: Link

    ECONOMIC DATA
    10:30 a.m. Dallas Fed Manufacturing Business Index
    11:30 a.m. 6-Month Bill Auction
    11:30 a.m. 3-Month Bill Auction
    1 p.m. 2-Year Note Auction
    1:15 p.m. Chicago Fed President Evans Speaks
    6:30 p.m. FOMC Member Kaplan Speaks
    ANALYST RATINGS
    Piper Jaffray upgraded Best Buy Co (NYSE: BBY) from Neutral to Overweight
    Wells Fargo upgraded Allscripts Healthcare (NASDAQ: MDRX) from Market Perform to Outperform
    Mizuho upgraded Universal Health Service (NYSE: UHS) from Neutral to Buy
    Piper Jaffray downgraded The Michaels Companies (NASDAQ: MIK) from Overweight to Neutral
    JMP Securities downgraded KB Home (NYSE: KBH) from Market Outperform to Market Perform
    Raymond James downgraded Sierra Wireless Inc. (NASDAQ: SWIR) from Outperform to Market Perform

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

  • [By David Zeiler]

    Fear that expense could return if Obamacare is repealed hammered hospital stocks on Nov. 9. HCA Holdings Inc. (NYSE: HCA) fell almost 11%. Universal Health Services Inc. (NYSE: UHS) slipped nearly 7%. And Tenet Healthcare Corp. (NYSE: THC) plummeted almost 25%.

  • [By Paul Ausick]

    Universal Health Services Inc. (NYSE: UHS) lost 8.4% Wednesday to post a new 52-week low of $1/99.81 after closing Tuesday at $108.99. The 52-week high is $139.77. Volume of around 5.8 million was nearly 6 times the daily average of around 1 million shares traded. Raymond James downgraded the stock this morning on news of another request for information from the company related to a federal investigation.

Top 10 Stocks To Watch For 2018: Chuy's Holdings, Inc.(CHUY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows El Pollo LoCo Holdings stabilizing over thepast two yearswhile potentialpeers like large cap Chipotle Mexican Grill, Inc (NYSE: CMG) andsmall capsFiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY)have performed better in the past and appear to be in downtrends for the past 1 1/2 years:

  • [By Peter Graham]

    A long term performance chart shows El Pollo LoCo Holdings having fallen below its IPO price for retail investors, butsharesappear to have stabilized over the past year and a halfwhile potentialpeers like small capFiesta Restaurant Group Inc (NASDAQ: FRGI) and large cap Chipotle Mexican Grill, Inc (NYSE: CMG) have performed better in the past and small cap Chuy’s Holdings Inc (NASDAQ: CHUY) is moving sideways:

  • [By Peter Graham]

    A long term performance chart shows Del Taco Restaurants now outperforming Mexican restaurant stock peers such as mid cap Chipotle Mexican Grill, Inc (NYSE: CMG) and small caps El Pollo LoCo Holdings Inc (NASDAQ: LOCO), Fiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY) have mostly been drifting lower lately:

  • [By Peter Graham]

    A long term performance chart shows Chipotle Mexican Grills shares back to breakeven while of the small caps peers, El Pollo LoCo Holdings Inc (NASDAQ: LOCO) has had the worst performance, Fiesta Restaurant Group Inc (NASDAQ: FRGI) is off its 2015s peak and Chuy’s Holdings Inc (NASDAQ: CHUY) has been a mixed performer:

Top 10 Stocks To Watch For 2018: Dow Treasuries(DV)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart of Apollo Education Group along with peersITT Educational Services, Inc (NYSE: ESI) and DeVry Education Group Inc (NYSE: DV) reflect the headwinds from the Obama administration:

Top 10 Stocks To Watch For 2018: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

  • [By Javier Hasse]

    On the other hand, Cara Therapeutics Inc (NASDAQ: CARA) was up almost 1.9 percent in what also looked like a correction of the 1.6 percent gain registered over the regular trading session.

Top 10 Stocks To Watch For 2018: Voyager Therapeutics, Inc.(VYGR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) got a boost, shooting up 20 percent to $13.10 after the company announced 'positive' results from ongoing Phase 1b trial of VY-AADC01 for advanced Parkinson's disease.

Top 10 Stocks To Watch For 2018: NanoString Technologies, Inc.(NSTG)

Advisors’ Opinion:

  • [By Lisa Levin]

    NanoString Technologies Inc (NASDAQ: NSTG) was down, falling around 21 percent to $18.06 after the company issued weak revenue forecast for FY2016.

Top 10 Stocks To Watch For 2018: Midatech Pharma PLC(MTP)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
    My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
    DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
    CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
    China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
    Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
    Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
    Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
    Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
    EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Top 10 Stocks To Watch For 2018: Big 5 Sporting Goods Corporation(BGFV)

Advisors’ Opinion:

  • [By Nicholas Rossolillo]

    Dick’s Sporting Goods (NYSE:DKS) and Big 5 Sporting Goods (NASDAQ:BGFV) have both had a great 2016. As far as stock performance goes, Big 5 is the winner this year. But which company is in better shape for the new year?

safe investments

Andy Friedman Answers Top 7 Advisor Tax Bill Questions

Americo Introduces a Single-Premium Immediate LTCI Policy

Will Bitcoin Fever Push 2018 Price to $20,000? $100,000?

While Congress irons out the differences between the tax bills proposed by the House and Senate, taxpayers have been living in limbo, and putting year-end tax planning on hold.

To see how the tax bills that passed each chamber would affect Americans across a range of incomes and circumstances, Bloomberg turned to Tim Steffen, director of advanced planning at Baird Private Wealth Management.

(Related: 4 Year-End Tax Tips as Overhaul Looms)

Steffen provided eight scenarios, from a Manhattan homeowner with a $2 million salary to a renter in Milwaukee making $40,000.

Most taxpayers would do better under the Senate bill, the results show — but that’s for the first year. Keep in mind that GOP senators crafted their individual tax changes to expire in 2026. Most of the House bill’s individual tax changes are intended as permanent — except for a $300 tax credit for qualifying individuals that would expire after 2022. But the Senate’s tough budget rules mean that its “sunset” provisions are more likely to become law.

safe investments: Mayne Pharma Group Limited (MAYNF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ

stock exchange hours

FRED DUFOUR/AFP/Getty Images

Why do we make things so complicated? Take retirement accounts for example. It seems like a simple concept. Enable people to save money tax-deferred during their working years, and then tax the investments when they are withdrawn from the account in retirement.

Yet our beloved government has managed to complicate this simple concept. Let’s start with the types of retirement accounts. If you think there is just a 401k or IRA, think again. Here’s just a partial list:

• Traditional 401k

• Roth 401k

• Self-Directed 401k

• Safe-Harbor 401k

• Tiered Profit Sharing 401k

• Simple 401k (my personal favorite)

• Individual Retirement Arrangement (IRA)

• Roth IRA

• SEP IRA

• Inherited IRA

stock exchange hours: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

stock exchange hours: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By Javier Hasse]

    On the other hand, Cara Therapeutics Inc (NASDAQ: CARA) was up almost 1.9 percent in what also looked like a correction of the 1.6 percent gain registered over the regular trading session.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

stock exchange hours: Sociedad Quimica y Minera S.A.(SQM)

Advisors’ Opinion:

  • [By Beth McKenna]

    Most investors interested in gaining exposure to the lithium space should stick with investing in one or more of the large players listed on a major U.S. stock exchange:Albemarle Corporation(NYSE:ALB), FMC Corp. (NYSE:FMC), andSociedad Quimica y Minera de Chile(NYSE:SQM), or SQM. Smaller players are speculative to varying degrees, and most are unprofitable.

stock exchange hours: S&P Smallcap 600(PH)

Advisors’ Opinion:

  • [By Charles Mizrahi, President and CEO, Hampton Investors, Inc.]

    Parker Hannifin (PH) generates strong revenue from its aerospace division, while its primary industrial segment is lagging.

    Overall, we like the company’s balanced portfolio. PH had solid order rates this past year with backlog of $3.6 billion between its industrial and aerospace segments.

stock exchange hours: Lumber Liquidators Holdings, Inc(LL)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap hardwood flooring stockLumber Liquidators Holdings Inc (NYSE: LL) reportedQ2 2017 earnings before the market opened this morning with better than expected earnings sending shares soaring as the Company went into earnings with short interest of 24.68% according to Highshortinterest.com. Net sales increased10.7% to $263.5 million as net sales in comparable stores increased 8.8% driven by a 5.3% increase in the number of customers invoiced and a 3.5% increase in the average sale. Merchandise sales in comparable stores grew 6.1% in the quarter whilenet sales in non-comparable stores increased $4.4 million. The Company did not open any stores during the second quarter of 2017 with the total store count remaining at 385 as of June 30, 2017. Net income was $4.5 million versusa net loss of $12.2 million for the first profit in the wake of a 2015 “60 Minutes” report that claimed the Companys laminate flooring contained high levels of cancer-causing formaldehyde.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap hardwood flooring stockLumber Liquidators Holdings Inc (NYSE: LL) is scheduled for before the market opens onTuesday (February 21th). Lumber Liquidators Holdingshad been ahighflying stock until the middle of 2013 when shares were hit be allegations that the companys flooring products contained illegal levels of formaldehyde. Shares then took another hit on reports that the Department of Homeland Security andthe USFish and Wildlife Servicehad executed a sealed court-issuedsearch/raid on theheadquarters for possible sourcing violations.Lumber Liquidators Holdingslater won a favorable ruling in a California lawsuit filed under the state’s Proposition 65 covering cancer-causing chemicals and agreed to pay $2.5 million (without admitting wrongdoing) to settle a civil matter with the California Air Resources Board.

  • [By Jeremy Bowman]

    Shares ofLumber Liquidators Holdings, Inc.(NYSE:LL) were moving higher last month, though there was little company-specific news out on the stock. The retailer of wood flooring and other related products had been battered in recent years after a scandal involving illegally treated flooring, but investor confidence seemed to be returning along with a general uptick in home-improvement stocks. According to data from S&P Global Market Intelligence, the stock rose 18.4% in March.

stock exchange hours: Sandstorm Gold Ltd(SAND )

Advisors’ Opinion:

  • [By Rich Duprey]

    Sandstorm Gold (NYSEMKT:SAND) has outperformed the precious metal itself over the past year, with shares rising 35% year to date. Last month it reported third-quarter profits of $7 million, a big U-turn from 2015, when it suffered losses of $5.5 million. In fact, its entire operation was doing better with greater production: lower cash costs, but higher cash margins; and greater operating cash flows, all of which allowed it to pay down its revolving credit facility. That means it has no bank debt and its entire $110 million revolving credit facility is available to make acquisitions.

micro cap stocks

The Q3 2016 earnings report for small cap proppant and fracking stock U.S. Silica Holdings Inc (NYSE: SLCA)is scheduled for after the market closes onThursday (November 4th). Proppant and fracking stocks have beencrushed by low oil prices, but the latest technical chart for U.S. Silica Holdings shows a nice comeback until recent weeks:

A long term performance chart shows U.S. Silica Holdings and Hi-Crush Partners LP (NYSE: HCLP) both peaking around mid-2014 while CARBO Ceramics Inc (NYSE: CRR)hasv is struggling to survive:

micro cap stocks: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest increase to 7.78 million shares from the previous level of 7.38 million. Shares closed most recently at $145.34, in a 52-week trading range of $133.64 to $176.85.

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

micro cap stocks: B&G Foods, Inc.(BGS)

Advisors’ Opinion:

  • [By Chris Lange]

    B&G Foods Inc. (NYSE: BGS) madewaves late on Friday after the company announced its most recent acquisition. B&G has now acquired Victoria Fine Foods from Huron Capital Partners and other sellers for roughly $70 million in cash.

micro cap stocks: Caladrius Biosciences, Inc.(CLBS)

Advisors’ Opinion:

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)
  • [By Lisa Levin]

    Caladrius Biosciences Inc (NASDAQ: CLBS) shares shot up 14 percent to $5.83 after the company posted upbeat Q4 results.

    Shares of Norsat International Inc (USA) (NYSE: NSAT) got a boost, shooting up 22 percent to $9.85 after the company reported the receipt of new indication of interest by Privet Fund Management LLP at $10.25 per share.

  • [By Chris Lange]

    Caladrius Biosciences Inc. (NASDAQ: CLBS) watchedits shares soar on Thursday after the company announced a private placement offering. In terms of the specifics, the company entered into securities purchase agreements with several accredited investors for the sale of 4,449,153 shares of its common stock in private placements of $21 million.

micro cap stocks: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By Javier Hasse]

    On the other hand, Cara Therapeutics Inc (NASDAQ: CARA) was up almost 1.9 percent in what also looked like a correction of the 1.6 percent gain registered over the regular trading session.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

micro cap stocks: Limelight Networks Inc.(LLNW)

Advisors’ Opinion:

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)